These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1976 related articles for article (PubMed ID: 31562799)

  • 21. Homologous Recombination Deficiency Testing to Inform Patient Decisions About Niraparib Maintenance Therapy for High-Grade Serous or Endometrioid Epithelial Ovarian Cancer: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2023; 23(5):1-188. PubMed ID: 37637244
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Niraparib: First Global Approval.
    Scott LJ
    Drugs; 2017 Jun; 77(9):1029-1034. PubMed ID: 28474297
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial.
    Del Campo JM; Matulonis UA; Malander S; Provencher D; Mahner S; Follana P; Waters J; Berek JS; Woie K; Oza AM; Canzler U; Gil-Martin M; Lesoin A; Monk BJ; Lund B; Gilbert L; Wenham RM; Benigno B; Arora S; Hazard SJ; Mirza MR
    J Clin Oncol; 2019 Nov; 37(32):2968-2973. PubMed ID: 31173551
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Niraparib: A Review in Ovarian Cancer.
    Heo YA; Duggan ST
    Target Oncol; 2018 Aug; 13(4):533-539. PubMed ID: 30073633
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Niraparib maintenance in frontline management of ovarian cancer: a cost effectiveness analysis.
    Barrington DA; Tubbs C; Smith HJ; Straughn JM; Senter L; Cohn DE
    Int J Gynecol Cancer; 2020 Oct; 30(10):1569-1575. PubMed ID: 32753559
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.
    Coleman RL; Fleming GF; Brady MF; Swisher EM; Steffensen KD; Friedlander M; Okamoto A; Moore KN; Efrat Ben-Baruch N; Werner TL; Cloven NG; Oaknin A; DiSilvestro PA; Morgan MA; Nam JH; Leath CA; Nicum S; Hagemann AR; Littell RD; Cella D; Baron-Hay S; Garcia-Donas J; Mizuno M; Bell-McGuinn K; Sullivan DM; Bach BA; Bhattacharya S; Ratajczak CK; Ansell PJ; Dinh MH; Aghajanian C; Bookman MA
    N Engl J Med; 2019 Dec; 381(25):2403-2415. PubMed ID: 31562800
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Niraparib Population Pharmacokinetics and Exposure-Response Relationships in Patients With Newly Diagnosed Advanced Ovarian Cancer.
    Monk BJ; Romero I; Graybill W; Churruca C; O'Malley DM; Knudsen AØ; Yap OWS; Baurain JF; Rose PG; Denys H; Ghamande S; Pisano C; Fabbro M; Braicu EI; Calvert PM; Amit A; Prendergast E; Taylor A; Kheibarshekan L; Zhang ZY; Zajic S; Jewell RC; Gupta D; González-Martín A
    Clin Ther; 2024 Aug; 46(8):612-621. PubMed ID: 39019698
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Niraparib - A promising drug with hematological toxicity.
    Patibandla NS; Monga DK
    J Oncol Pharm Pract; 2019 Oct; 25(7):1749-1753. PubMed ID: 30293481
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real-world adverse events with niraparib 200 mg/day maintenance therapy in ovarian cancer: a retrospective study.
    Gallagher JR; Heap KJ; Carroll S; Travers K; Harrow B; Westin SN
    Future Oncol; 2019 Dec; 15(36):4197-4206. PubMed ID: 31707856
    [No Abstract]   [Full Text] [Related]  

  • 30. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
    Ledermann JA; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Rowe P; Lowe E; Hodgson D; Sovak MA; Matulonis U
    Lancet Oncol; 2016 Nov; 17(11):1579-1589. PubMed ID: 27617661
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Phase 3 Randomized Clinical Trial.
    Li N; Zhu J; Yin R; Wang J; Pan L; Kong B; Zheng H; Liu J; Wu X; Wang L; Huang Y; Wang K; Zou D; Zhao H; Wang C; Lu W; Lin A; Lou G; Li G; Qu P; Yang H; Zhang Y; Cai H; Pan Y; Hao M; Liu Z; Cui H; Yang Y; Yao S; Zhen X; Hang W; Hou J; Wang J; Wu L
    JAMA Oncol; 2023 Sep; 9(9):1230-1237. PubMed ID: 37440217
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Budget impact analysis of niraparib and olaparib for maintenance treatment of platinum-sensitive, recurrent ovarian cancer in the US.
    Wu L; Zhong L
    J Med Econ; 2019 Feb; 22(2):187-195. PubMed ID: 30522378
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Niraparib Slows Ovarian Cancer Progression.
    Cancer Discov; 2016 Dec; 6(12):OF2. PubMed ID: 27810860
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial.
    Banerjee S; Moore KN; Colombo N; Scambia G; Kim BG; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Oza A; González-Martín A; Aghajanian C; Bradley WH; Holmes E; Lowe ES; DiSilvestro P
    Lancet Oncol; 2021 Dec; 22(12):1721-1731. PubMed ID: 34715071
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities.
    Moore KN; Mirza MR; Matulonis UA
    Gynecol Oncol; 2018 Apr; 149(1):214-220. PubMed ID: 29397193
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24.
    Mirza MR; Bergmann TK; Mau-Sørensen M; Christensen RD; Åvall-Lundqvist E; Birrer MJ; Jørgensen M; Roed H; Malander S; Nielsen F; Lassen U; Brøsen K; Bjørge L; Mäenpää J
    Cancer Chemother Pharmacol; 2019 Oct; 84(4):791-798. PubMed ID: 31375879
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial.
    Mirza MR; González-Martín A; Graybill WS; O'Malley DM; Gaba L; Stephanie Yap OW; Guerra EM; Rose PG; Baurain JF; Ghamande SA; Denys H; Prendergast E; Pisano C; Follana P; Baumann K; Calvert PM; Korach J; Li Y; Malinowska IA; Gupta D; Monk BJ
    Cancer; 2023 Jun; 129(12):1846-1855. PubMed ID: 37060236
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study.
    O'Cearbhaill RE; Pérez-Fidalgo JA; Monk BJ; Tusquets I; McCormick C; Fuentes J; Moore RG; Vulsteke C; Shahin MS; Forget F; Bradley WH; Hietanen S; O'Malley DM; Dørum A; Slomovitz BM; Baumann K; Selle F; Calvert PM; Artioli G; Levy T; Kumar A; Malinowska IA; Li Y; Gupta D; González-Martín A
    Gynecol Oncol; 2022 Jul; 166(1):36-43. PubMed ID: 35550709
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Niraparib in Japanese patients with platinum-sensitive recurrent ovarian cancer: final results of a multicenter phase 2 study.
    Itamochi H; Takeshima N; Hamanishi J; Hasegawa K; Matsuura M; Miura K; Nagao S; Nakai H; Tanaka N; Tokunaga H; Nishio S; Watari H; Yokoyama Y; Kase Y; Sumino S; Kato A; Suri A; Yasuoka T; Takehara K
    J Gynecol Oncol; 2024 Sep; 35(5):e115. PubMed ID: 39058367
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Niraparib for the treatment of ovarian cancer.
    Kanjanapan Y; Lheureux S; Oza AM
    Expert Opin Pharmacother; 2017 Apr; 18(6):631-640. PubMed ID: 28299955
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 99.